Asana BioSciences, LLC

Release Summary

Asana BioSciences, LLC, an oncology-focused, clinical stage biopharmaceutical company, announces FDA acceptance of its third IND application in oncology for ASN003, a selective RAF/PI3K inhibitor

Asana BioSciences, LLC